№ lp_1_24647
File format: docx Character count: 7868 File size: 141 KB
This document provides a detailed template for submitting key information on biotherapeutic products, such as rituximab or trastuzumab, that are approved by stringent regulatory authorities, for WHO prequalification purposes.
Year: 2021
Region / city: Worldwide
Topic: Biotherapeutic Product Documentation
Document type: Guidelines
Organization / institution: World Health Organization (WHO)
Author: World Health Organization (WHO)
Target audience: Regulatory authorities, pharmaceutical companies, healthcare professionals
Period of validity: Not specified
Approval date: Not specified
Date of changes: Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Quality Information Summary (QIS) of the Biotherapeutic Product Approved by Stringent Regulatory Authority (SRA)(QIS-BTP-SRA)
Year: 2023
Region / City: Global
Topic: Biotherapeutic Product Prequalification
Document Type: Guidelines
Organization / Institution: World Health Organization (WHO)
Author: WHO
Target Audience: Regulatory Authorities, Pharmaceutical Companies
Validity Period: Ongoing
Approval Date: Not specified
Date of Changes: Not specified
Quality Information Summary (QIS) of the Biotherapeutic Product Approved by Stringent Regulatory Authority (SRA)(QIS-BTP-SRA)
Year: 2023
Region / City: Global
Topic: Biotherapeutic Product Prequalification
Document Type: Guidelines
Organization / Institution: World Health Organization (WHO)
Author: WHO
Target Audience: Regulatory Authorities, Pharmaceutical Companies
Validity Period: Ongoing
Approval Date: Not specified
Date of Changes: Not specified
Quality Information Summary (QIS) of the Biotherapeutic Product Approved by Stringent Regulatory Authority (SRA) (QIS-BTP-SRA)
Year: 2021
Region / City: N/A
Topic: Biotherapeutic Product Prequalification
Document Type: Template
Organization / Institution: World Health Organization (WHO)
Author: WHO
Target Audience: Regulatory Authorities, Manufacturers
Effective Period: N/A
Approval Date: N/A
Date of Changes: N/A
RBX7455, a Room Temperature-Stable, Orally-Administered Investigational Live Biotherapeutic, Phase 1 Study for Recurrent Clostridioides difficile Infections
Year: 2026
Region / City: Rochester, MN, USA
Topic: Microbiome modulation in Clostridioides difficile infection
Document Type: Clinical trial report
Institution: Mayo Clinic; Rebiotix Inc; BioRankings LLC
Authors: Sahil Khanna, MBBS; Darrell S. Pardi, MD; Courtney Jones; William D. Shannon, PhD, MBA; Carlos Gonzalez, MS; Ken Blount, PhD
Target Audience: Medical researchers, gastroenterologists, microbiologists
Study Phase: Phase 1
Treatment: RBX7455 orally administered live biotherapeutic
Sample Type: Fecal samples from study participants
Outcome Measures: Safety, efficacy, microbiome composition shifts
Time Points: Baseline, Day 1, Week 1, Week 4, Week 8, Week 12, Week 24
Analysis Methods: Dirichlet multinomial fitting, repeated measures analysis (DMRepeat)
Publication References: La Rosa PS et al., PLoS One 2012; Shannon WD, BioRankings Technical Report #3
Quality Information Summary of Finished Pharmaceutical Products Approved by Stringent Regulatory Authorities (SRA)
Year: 2014
Region / City: Global
Topic: Pharmaceutical Product Prequalification
Document Type: Guideline
Organization / Institution: World Health Organization (WHO)
Author: World Health Organization
Target Audience: Pharmaceutical manufacturers, regulatory bodies
Effective Period: Not specified
Approval Date: 2014
Modification Date: Not specified
Quality Information Summary (QIS) of the Finished Pharmaceutical Product (FPP) Approved by the Reference Stringent Regulatory Authority (SRA) for use outside of the SRA Region(QIS-SRA-MED-crp)
Note: Year
Topic: Pharmaceutical product, regulatory approval, prequalification
Document type: Template
Organization / institution: WHO
Target audience: Regulatory authorities, pharmaceutical manufacturers
Quality Information Summary (QIS) of the Biotherapeutic Product Approved by Stringent Regulatory Authority (SRA)(QIS-BTP-SRA)
Year: 2023
Region / City: Global
Topic: Biotherapeutic Product Prequalification
Document Type: Guidelines
Organization / Institution: World Health Organization (WHO)
Author: WHO
Target Audience: Regulatory Authorities, Pharmaceutical Companies
Validity Period: Ongoing
Approval Date: Not specified
Date of Changes: Not specified
Quality Information Summary (QIS) of the Biotherapeutic Product Approved by Stringent Regulatory Authority (SRA) (QIS-BTP-SRA)
Year: 2021
Region / City: N/A
Topic: Biotherapeutic Product Prequalification
Document Type: Template
Organization / Institution: World Health Organization (WHO)
Author: WHO
Target Audience: Regulatory Authorities, Manufacturers
Effective Period: N/A
Approval Date: N/A
Date of Changes: N/A
Table S1. Demographic, alcohol use, and network characteristics of the Full, Stringent, and Inclusive samples for the simulation study
Year: 2023
Region / city: N/A
Topic: Simulation study of demographic and network characteristics, alcohol use
Document type: Research table
Institution: N/A
Author: N/A
Target audience: Researchers, scholars in social science and network analysis
Period of validity: N/A
Approval date: N/A
Date of changes: N/A
Topics: SRAQIS-BTP-SRA Biotherapeutic Stringent